Point-of-Care RNA-Based Diagnostic Device for COVID-19

Yang, Ting; Wang, Yung-Chih; Shen, Ching Fen; Cheng, Chao

doi:10.3390/diagnostics10030165

Cited by 127 publications

(115 citation statements)

References 5 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…A fluorescence-based quantitative PCR assay based on SARS-CoV-2 N and ORF1ab regions has been developed (Wang et al 2020b). Moreover, testing for COVID-19 requires travelling to a clinical setting that could lead to increased risk of disease transmission hence a rapid, cheap, user-friendly and sensitive diagnostic tool must be developed for use by ordinary people in their homes (Yang et al, 2020b). In this context, a potential RNA-based POCT diagnostic device which combines a LAMP assay technology and a paper-based POCT was described as a home-based highly accessible and sensitive COVID-19 diagnostic tool with the additional advantage of smartphone integration enabling the individuals to record and share the results with healthcare workers and subsequent clinical care (Yang et al, 2020b).…”

Section: Covid-19 Clinical Pathologymentioning

confidence: 99%

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

Mandegary¹,

Al-Ahmed²,

Sah³

et al. 2020

Preprint

View full text Add to dashboard Cite

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China has resulted in an outbreak in China which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 175 countries while affecting nearly 500,000 persons and causing more than 22,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. Till date, no clinically proclaimed, proven therapeutic antibodies or specific drugs and therapeutics, and vaccines have turned up. Several molecular diagnostic tests such as Real Time-PCR, isothermal loop-mediated amplification of coronavirus (i-LACO), full genome analysis by next-generation sequencing (NGS), multiplex nucleic acid amplification, and microarray-based assays are in use currently for the laboratory confirmation of this CoV infection. In this review article, we describe the basic molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

show abstract

Section: Covid-19 Clinical Pathologymentioning

confidence: 99%

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

Mandegary¹,

Al-Ahmed²,

Sah³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…As the number of confirmed cases of COVID-19 rises rapidly throughout the world, more and more nations continue to require reliable testing. A rapid, inexpensive, and easy-to-use point-of-care diagnostic device integrated with a smartphone could reduce transportation needs, lower the risk of spreading infection, alleviate the strain on the healthcare system, and mitigate the cost of testing for both individuals and governments 31 . Unfortunately, scaling up production of available COVID-19 diagnostics, as well as personal protective equipment, remain an ongoing challenge in the fight against this disease.…”

Section: Point-of-care Tests To Diagnose Covid-19mentioning

confidence: 99%

Current and emerging diagnostic tests available for the novel COVID-19 global pandemic

Mboowa

2020

AAS Open Res

View full text Add to dashboard Cite

On March 11, 2020 the World Health Organization (WHO) upgraded the status of the coronavirus disease 2019 (COVID-19) outbreak from epidemic to a global pandemic. This infection is caused by a novel coronavirus, SARS-CoV-2. Several rapid diagnostic tests have been developed at an astonishing pace; however, COVID-19 requires more highly specific rapid point-of-care diagnostic tests. This review describes the currently available testing approaches, as well as the available test assays including the Xpert® Xpress SARS-CoV-2 test (takes ~45 min) and Abbott ID COVID-19 test (5 min) as easy to use point-of-care tests for diagnosis of novel COVID-19 that have so far received the US Food and Drug Administration emergency use authorizations clearance. This review is correct as of the date published and will be updated as more diagnostic tests come to light.

show abstract

“…For early diagnosis, chest computed tomography (CT) (Bai et al, 2020;Bernheim et al, 2020;Li and Xia, 2020;Pan et al, 2020a) was used whereas in the analytical stage, realtime reverse-transcriptase polymerase chain reaction (RT-PCR) Corman et al, 2020;Lan et al, 2020;Loeffelholz and Tang, 2020) remains the standard test for the etiologic diagnosis of SARS-CoV-2 (Ai et al, 2020;Fang et al, 2020). Recently, antibody and CRISPR based techniques are being introduced as supplemental tools for rapid diagnosis Ding et al, 2020;Yang et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2

Mahari¹,

Roberts²,

Shahdeo³

et al. 2020

Preprint

182

153

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, also known as 2019-nCov or nCovid-19) outbreak has become a huge public health issue due to its rapid transmission making it a global pandemic. Currently, there are no vaccines or drugs available for nCovid-19, hence early detection is crucial to help and manage the outbreak. Here, we report an inhouse built biosensor device (eCovSens) and compare it with a commercial potentiostat machine for the detection of nCovid-19 spike protein antigen (nCovid-19 Ag) in spiked saliva samples. A potentiostat based sensor was fabricated using fluorine doped tin oxide electrode (FTO) drop casted with gold nanoparticle (AuNPs) and immobilized with nCovid-19 monoclonal antibody (nCovid-19 Ab) to measure change in the electrical conductivity. Similarly, eCovSens was used to measure change in electrical conductivity by immobilizing nCovid-19 Ab on screen printed carbon electrode (SPCE). The performances of both sensors were recorded upon interaction of nCovid-19 Ab with its specific nCovid-19 Ag. Under optimum conditions, the FTO based immunosensor and proposed SPCE-based biosensor device displayed high sensitivity for early detection of nCovid-19 Ag, ranging from 1 fM to 1 µM. Our in-house developed eCovSens device can successfully detect nCovid-19 Ag at 10 fM concentration in standard buffer that is in close agreement with FTO/AuNPs sensor where AuNPs were used for the amplification of the electrical signal. The limit of detection (LOD) was found to be 90 fM with eCovSens and 120 fM with potentiostst in case of spiked saliva samples. The proposed portable point of care (PoC) eCovSens device can be used as an alternative diagnostic tool for the rapid (within 10-30 s) detection of nCovid-19 Ag traces directly in patient saliva samples that displayed high sensitivity, stability, and specificity.

show abstract

Point-of-Care RNA-Based Diagnostic Device for COVID-19

Abstract: At the end of 2019, the novel coronavirus disease (COVID-19), a fast-spreading respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported in Wuhan, China and has now affected over 123 countries globally [...]

Cited by 127 publications

References 5 publications

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

Current and emerging diagnostic tests available for the novel COVID-19 global pandemic

eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2

Contact Info

Product

Resources

About

Point-of-Care RNA-Based Diagnostic Device for COVID-19

Abstract: At the end of 2019, the novel coronavirus disease (COVID-19), a fast-spreading respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported in Wuhan, China and has now affected over 123 countries globally [...]

Cited by 127 publications

References 5 publications

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus &ndash; A Review

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus &ndash; A Review

Current and emerging diagnostic tests available for the novel COVID-19 global pandemic

eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2

Contact Info

Product

Resources

About

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review